Phase 1 study of anti-PD-L1 durvalumab plus gefitinib in TKI-naïve patients with EGFR-mutant NSCLC

Don Gibbons, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a phase 1 expansion study evaluating the efficacy, safety and tolerability of durvalumab, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib for tyrosine kinase inhibitor-naïve patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC):


Progress in the treatment of ALK-positive non-small cell lung cancer

David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, provides an overview of the improvements in the treatment of patients with non-small cell lung cancer (NSCLC) carrying the anaplastic lymphoma kinase (ALK) gene rearrangement, including ALK-targeted therapies with improved blood–brain barrier penetrance and understanding of resistance mechanisms:


Optimal TKI use for oncogene-addicted non-small cell lung cancer

Kenneth O'Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses optimizing the use of tyrosine kinase inhibitors (TKIs) and movement towards personalized approaches for the treatment of patients with “oncogene-addicted” non-small cell lung cancer, including epidermal growth factor receptor (EGFR)-mutant and anaplastic lymphoma kinase (ALK)-mutant patients:


CheckMate 171: Phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer

Enriqueta Felip, MD, PhD, from Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses CheckMate 171, a multicenter phase 2 trial of nivolumab, an anti-PD-1 monoclonal antibody, in patients with stage IIIB/IV squamous cell non-small cell lung cancer who have received at least one prior systemic treatment:


ASSESS trial: Blood test for EGFR mutation in advanced non-small cell lung cancer

Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses ASSESS, a trial of the utility of circulating-free tumor DNA in the plasma for the detection of epidermal growth factor receptor (EGFR) mutation status in patients with advanced non-small cell lung cancer:


Blood samples for detecting actionable oncogenic mutations in lung cancer

Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the identification of actionable mutations in tumors for the development of personalized medicine for patients with lung cancer, including for the identification of patients with acquired resistance associated with T790M mutation:


Targeting PD-1 and PD-L1 for lung cancer therapy

Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, explains the development of antibodies targeting the programmed death ligand 1 (PD-L1) and its receptor, programmed death 1 (PD-1) for the treatment of patients with non-small cell lung cancer (NSCLC), including clinical trials evaluating the integration of PD-1/PD-L1–blocking antibodies with existing standard-of-care approaches:


Differences in expression of predictive biomarkers between primary and metastatic NSCLC

Zoran Gatalica, MD, DSc, from Caris Life Sciences, Phoenix, AZ, discusses a study evaluating the differences in expression of multiple biomarkers of targeted biological therapies, immune checkpoint inhibitors and chemotherapeutic agents between primary and metastatic tumors in patients with non-small cell lung cancer (NSCLC):


Biomarkers and lung cancer: Current status

Keith Kerr, BSc, MB ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, United Kingdom, discusses biomarker-based selection of therapy and the progress in understanding clinically relevant biomarkers in patients with lung cancer:


Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC

Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial of the efficacy and safety of BI 1482694 (HM61713), a third-generation epidermal growth factor receptor (EGFR) mutant-specific tyrosine kinase inhibitor (TKI), for the treatment of patients with T790M-positive non-small cell lung cancer (NSCLC):